Prospective SecurAcath Subcutaneous Securement Trial (SecurAcath)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00903539
Recruitment Status : Completed
First Posted : May 18, 2009
Last Update Posted : January 31, 2012
Information provided by (Responsible Party):
Interrad Medical

May 14, 2009
May 18, 2009
January 31, 2012
January 2009
May 2011   (Final data collection date for primary outcome measure)
Device Securement Success: defined as the percent of devices implanted and explanted without malfunction or device related complications attributed to the subcutaneous securement system. [ Time Frame: Timeframe is the length of time the patient has the catheter in place. Can vary depending on the indication for the catheter (anywhere from 48 hours post-procedure to 6 months or more). ]
Same as current
Complete list of historical versions of study NCT00903539 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Prospective SecurAcath Subcutaneous Securement Trial
Prospective SecurAcath Subcutaneous Securement Clinical Trial
To prospectively monitor the safety and performance of the catheter securement device in subjects whose catheter is secured with the Interrad Medical SecureAcath device.

Peripherally inserted central catheters (PICCs) and Central Venous Catheter (CVC) are widely used to deliver fluids directly to the central venous system and can remain in place for as short as a few days to as long as months. One of the highest risks in the use of these catheters is infection, both local and systemic. Currently, these catheters are secured by either sutures or adhesive patches. Sutures can create additional potential entry points for bacteria whereas both sutures and adhesive securement patches hold the catheter hub to the skin resulting in increased difficulty cleaning around the catheter entry site. Furthermore, securing a catheter outside the skin away from the catheter entry point, as with sutures or adhesive securement patches may potentiate pistoning of the catheter which is also believed to possibly increase infection risks. A second risk of intravenous catheter use is dislodgement during normal use and site maintenance. These catheters are often manipulated multiple times a day for blood sampling or injection of fluids. During manipulation, the catheter can be dislodged thus requiring an unplanned replacement of the catheter.

Interrad Medical has developed a means to secure indwelling catheters using a small subcutaneous anchor. With this system, cleaning around the catheter entry site is made easier and can be more thorough. The system is also designed to minimize the risk of catheter dislodgement because once the anchor is deployed, the catheter remains secured. This may simplify dressing changes compared to adhesive devices such as Statlock, which requires the catheter be released from the device and therefore be unsecured during dressing changes.

The objective of this post-market study is to monitor the safety and performance of the SecurAcath when used to secure the catheter to the insertion site via a subcutaneous anchor. The data collected may provide insight for future enhancements to improve the safety and utility of the device. It also provides a means for an early warning of any identified safety issues, and allows physicians to share their experiences thereby improve the quality of care provided to the patients.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients indicated to have a central catheter placed at a hospital or private practice clinic are included in the study population.
Central Venous Catheter
Device: SecurAcath Securement System
Subcutaneous catheter securement system
Other Name: PICC securement system
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 or older
  • Requires an intravenous catheter to be placed

Exclusion Criteria:

  • Inability to understand the study or a history of non-compliance with medical advice.
  • Unwilling or unable to sign Informed Consent Form (ICF).
  • Had a previous catheter placed in the same side within the last 3 months.
  • Known central venous thrombosis or occlusion or stenosis on the side of the body to be used for the catheter.
  • History of upper extremity venous thrombosis on the side of the body to be used for the catheter.
  • Known hypercoagulable disorder.
  • Diffuse skin inflammatory condition or rashes on the side to be used for the catheter line.
  • Peripheral chemotherapy therapy in the same side as that to be used for the catheter line within 3 months.
  • Known hypersensitivity to nickel.
  • Any infection associated with positive blood cultures that are still present after 48 hours of antibiotic therapy.
  • Previous mastectomy or axillary lymph node dissection on the same side as catheter implant.
  • Subjects on chronic or recurrent systemic steroid medications for 6 months or longer.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Interrad Medical
Interrad Medical
Not Provided
Not Provided
Interrad Medical
January 2012